FLT3 and non-small cell lung carcinoma: However, we found common features between FLT3(ITD)-positive AML cells and NSCLC cells, including strong resistance to DNA-damaging therapeutic agents due to high DNA repair system compared to wild-type FLT3 cells or normal cells.